IL130333A0 - Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists - Google Patents
Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonistsInfo
- Publication number
- IL130333A0 IL130333A0 IL13033397A IL13033397A IL130333A0 IL 130333 A0 IL130333 A0 IL 130333A0 IL 13033397 A IL13033397 A IL 13033397A IL 13033397 A IL13033397 A IL 13033397A IL 130333 A0 IL130333 A0 IL 130333A0
- Authority
- IL
- Israel
- Prior art keywords
- agonists
- prevention
- treatment
- receptor subtype
- subtype selective
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title abstract 2
- 229960002986 dinoprostone Drugs 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3356996P | 1996-12-20 | 1996-12-20 | |
PCT/IB1997/001483 WO1998027976A1 (en) | 1996-12-20 | 1997-11-27 | Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL130333A0 true IL130333A0 (en) | 2000-06-01 |
Family
ID=21871174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13033397A IL130333A0 (en) | 1996-12-20 | 1997-11-27 | Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists |
IL130333A IL130333A (en) | 1996-12-20 | 1999-06-07 | Use of pharmaceutical preparations containing selective agonists of the EP2 receptor subtype in the preparation of drugs to prevent bone loss, increase bone mass and treat disorders associated with low bone mass |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL130333A IL130333A (en) | 1996-12-20 | 1999-06-07 | Use of pharmaceutical preparations containing selective agonists of the EP2 receptor subtype in the preparation of drugs to prevent bone loss, increase bone mass and treat disorders associated with low bone mass |
Country Status (19)
Country | Link |
---|---|
US (1) | US6426359B1 (ko) |
EP (1) | EP0951282B1 (ko) |
JP (2) | JP2000507961A (ko) |
KR (1) | KR100359557B1 (ko) |
AT (1) | ATE390917T1 (ko) |
AU (1) | AU4881697A (ko) |
CA (1) | CA2275595C (ko) |
CY (1) | CY2610B2 (ko) |
DE (1) | DE69738613T2 (ko) |
DK (1) | DK0951282T3 (ko) |
ES (1) | ES2303341T3 (ko) |
HU (1) | HUP0001836A3 (ko) |
IL (2) | IL130333A0 (ko) |
MY (1) | MY132818A (ko) |
NZ (1) | NZ335770A (ko) |
PT (1) | PT951282E (ko) |
TW (1) | TW562677B (ko) |
WO (1) | WO1998027976A1 (ko) |
ZA (1) | ZA9711435B (ko) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
DE69738613T2 (de) | 1996-12-20 | 2009-04-30 | Pfizer Inc. | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten |
EP1000619A3 (en) * | 1998-06-23 | 2002-07-24 | Pfizer Products Inc. | Method for treating glaucoma |
US6414006B1 (en) | 1998-10-15 | 2002-07-02 | Merck Frosst Canada & Co. | Methods for inhibiting bone resorption |
WO2000029614A1 (en) * | 1998-11-12 | 2000-05-25 | Gemini Genomics Ab. | Human prostaglandin receptors and methods of use thereof |
HUP0200258A2 (hu) | 1999-03-05 | 2002-05-29 | The Procter & Gamble Co. | C16-telítetlen FP-szelektív prosztaglandin analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
CN1413190A (zh) * | 1999-12-22 | 2003-04-23 | 辉瑞产品公司 | 治疗骨质疏松的ep4受体选择性激动剂 |
US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
FR2812190B1 (fr) * | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
FR2812192B1 (fr) * | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
RU2004116318A (ru) * | 2001-11-30 | 2005-03-27 | Пфайзер Продактс Инк. (Us) | Фармацевтические композиции и споосбы введения селективных агонистов ep2-рецептора |
WO2004073591A2 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2) |
PL378748A1 (pl) * | 2003-03-04 | 2006-05-15 | Pfizer Products Inc. | Zastosowanie selektywnych agonistów receptora EP2 w leczeniu |
EP2422814A1 (en) * | 2003-07-25 | 2012-02-29 | Ono Pharmaceutical Co., Ltd. | Remedy for cartilage-related diseases |
WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
US7635716B2 (en) | 2005-01-14 | 2009-12-22 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
WO2007017687A2 (en) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Ep2 receptor agonists |
US7323591B2 (en) * | 2006-01-10 | 2008-01-29 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
WO2009065081A2 (en) * | 2007-11-14 | 2009-05-22 | Cayman Chemical Company | Prostaglandin e1 and e2 analogs for the treatment of various medical conditions |
WO2009140205A2 (en) * | 2008-05-15 | 2009-11-19 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4033996A (en) | 1973-04-25 | 1977-07-05 | Merck & Co., Inc. | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins |
US4018892A (en) | 1975-08-06 | 1977-04-19 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4112236A (en) | 1977-04-04 | 1978-09-05 | Merck & Co., Inc. | Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins |
AU615534B2 (en) | 1988-04-19 | 1991-10-03 | Teijin Limited | 2-substituted-2-cyclopentenones |
US5409911A (en) | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
US5605814A (en) | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
US5698598A (en) | 1995-08-04 | 1997-12-16 | Allergan | EP2 -receptor agonists as agents for lowering intraocular pressure |
DE69738613T2 (de) | 1996-12-20 | 2009-04-30 | Pfizer Inc. | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten |
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
-
1997
- 1997-11-27 DE DE69738613T patent/DE69738613T2/de not_active Expired - Lifetime
- 1997-11-27 WO PCT/IB1997/001483 patent/WO1998027976A1/en active IP Right Grant
- 1997-11-27 ES ES97911412T patent/ES2303341T3/es not_active Expired - Lifetime
- 1997-11-27 CA CA002275595A patent/CA2275595C/en not_active Expired - Fee Related
- 1997-11-27 AU AU48816/97A patent/AU4881697A/en not_active Abandoned
- 1997-11-27 IL IL13033397A patent/IL130333A0/xx active IP Right Grant
- 1997-11-27 JP JP10528575A patent/JP2000507961A/ja not_active Withdrawn
- 1997-11-27 NZ NZ335770A patent/NZ335770A/en not_active IP Right Cessation
- 1997-11-27 US US09/331,078 patent/US6426359B1/en not_active Expired - Fee Related
- 1997-11-27 PT PT97911412T patent/PT951282E/pt unknown
- 1997-11-27 KR KR1019997005528A patent/KR100359557B1/ko not_active IP Right Cessation
- 1997-11-27 EP EP97911412A patent/EP0951282B1/en not_active Expired - Lifetime
- 1997-11-27 AT AT97911412T patent/ATE390917T1/de active
- 1997-11-27 DK DK97911412T patent/DK0951282T3/da active
- 1997-11-27 HU HU0001836A patent/HUP0001836A3/hu unknown
- 1997-12-17 TW TW086119114A patent/TW562677B/zh active
- 1997-12-18 MY MYPI97006111A patent/MY132818A/en unknown
- 1997-12-19 ZA ZA9711435A patent/ZA9711435B/xx unknown
-
1999
- 1999-06-07 IL IL130333A patent/IL130333A/en not_active IP Right Cessation
-
2006
- 2006-05-22 JP JP2006141297A patent/JP2006290895A/ja active Pending
-
2008
- 2008-06-05 CY CY0800012A patent/CY2610B2/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DK0951282T3 (da) | 2008-07-14 |
US6426359B1 (en) | 2002-07-30 |
MY132818A (en) | 2007-10-31 |
PT951282E (pt) | 2008-06-09 |
NZ335770A (en) | 2005-01-28 |
ATE390917T1 (de) | 2008-04-15 |
JP2006290895A (ja) | 2006-10-26 |
WO1998027976A1 (en) | 1998-07-02 |
TW562677B (en) | 2003-11-21 |
CY2610B2 (en) | 2010-10-22 |
KR20000057680A (ko) | 2000-09-25 |
DE69738613D1 (de) | 2008-05-15 |
EP0951282A1 (en) | 1999-10-27 |
JP2000507961A (ja) | 2000-06-27 |
KR100359557B1 (ko) | 2002-11-08 |
ES2303341T3 (es) | 2008-08-01 |
ZA9711435B (en) | 1999-06-21 |
HUP0001836A3 (en) | 2001-05-28 |
DE69738613T2 (de) | 2009-04-30 |
CA2275595C (en) | 2003-08-05 |
EP0951282B1 (en) | 2008-04-02 |
CA2275595A1 (en) | 1998-07-02 |
HUP0001836A2 (hu) | 2000-09-28 |
IL130333A (en) | 2007-02-11 |
AU4881697A (en) | 1998-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2610B2 (en) | Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 a gonists | |
BG102690A (en) | Il-8 receptor antagonists | |
BG102726A (en) | Combined therapy for osteoporosis | |
PL331091A1 (en) | Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor | |
DE69626660D1 (en) | 2-alkylpyrrolidine | |
GB2333453A (en) | Colostrinin and uses thereof | |
YU20600A (sh) | Nova upotreba antagonista 5-ht3 receptora | |
YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
MX9704640A (es) | Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. | |
AU3508497A (en) | Androgen receptor modulator compounds and methods | |
BG102999A (en) | New 2,3-diasubstituted-4-(3h)-quinazolinons | |
UA43378C2 (uk) | Композиція для лікування респіраторного дистрес-синдрому новонароджених та респіраторного дистрес-синдрому дорослих | |
WO2000006085A3 (en) | Compounds and methods | |
ID27820A (id) | APLIKASI-APLIKASI PENGOBATAN POLIPEPTIDA MATURE FLINT (mFLINT) ATAU OPG3, BAGIAN KELOMPOK SUPER RESEPTOR TNF | |
EP0909561A3 (en) | Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder | |
BR9510499A (pt) | Antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados po il-5 | |
EP2241329A3 (en) | Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness | |
DK0946157T3 (da) | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte | |
AU3745795A (en) | Use of CCK-B receptor antagonists for the treatment of sleepdisorders | |
TR199900505T2 (ko) | ||
ZA978640B (en) | Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis. | |
DE3378979D1 (en) | 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents | |
IL139303A0 (en) | Treatment of arthritis and other similar conditions | |
AU5244998A (en) | Morphogen-induced regeneration of sense perceptory tissues | |
EP0880971A3 (en) | Macrophage stimulating protein for the treatment of pathologies of the nervous system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |